{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:22:29Z","timestamp":1791490949187,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["320030_182366"],"award-info":[{"award-number":["320030_182366"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004224","name":"Peter MacCallum Cancer Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1122347"],"award-info":[{"award-number":["GNT1122347"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001169","name":"Cancer Council Tasmania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001169","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.euf.2022.08.016","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:32:47Z","timestamp":1663633967000},"page":"114-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review"],"prefix":"10.1016","volume":"9","author":[{"given":"Jennifer","family":"Le Guevelou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2022.08.016_b0005","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0010","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2022.08.016_b0015","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0020","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2022.08.016_b0025","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrurol.2017.87","article-title":"Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach","volume":"14","author":"Siva","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2022.08.016_b0030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.radonc.2018.04.028","article-title":"Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005\u20132014","volume":"127","author":"Stenman","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0035","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1464-410X.1989.tb05253.x","article-title":"Nephrectomy in renal carcinoma with distant metastasis","volume":"63","author":"Onishi","year":"1989","journal-title":"Br J Urol"},{"key":"10.1016\/j.euf.2022.08.016_b0040","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","volume":"345","author":"Flanigan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2022.08.016_b0045","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2022.08.016_b0050","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","article-title":"Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial [published correction appears in JAMA Oncol. 2019 Feb 1;5(2):271]","volume":"5","author":"Bex","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0055","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/COC.0000000000000329","article-title":"Stereotactic ablative radiotherapy (SABR) for large renal tumors: a retrospective case series evaluating clinical outcomes, toxicity, and technical considerations","volume":"41","author":"Correa","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13014-018-0992-3","article-title":"A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma","volume":"13","author":"Correa","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0070","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.31156","article-title":"Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK): pooled analysis of SABR for primary RCC","volume":"124","author":"Siva","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2022.08.016_b0075","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2014.05.034","article-title":"Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"66","author":"Heng","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.08.016_b0080","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.euf.2022.08.016_b0085","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/2326-6066.CIR-14-0138","article-title":"PD-1 restrains radiotherapy-induced abscopal effect","volume":"3","author":"Park","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.euf.2022.08.016_b0090","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1158\/1078-0432.CCR-16-2946","article-title":"A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma","volume":"23","author":"Singh","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2022.08.016_b0095","doi-asserted-by":"crossref","first-page":"e000535","DOI":"10.1136\/esmoopen-2019-000535","article-title":"Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study","volume":"4","author":"Dengina","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.euf.2022.08.016_b0100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0105","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamaoncol.2020.6146","article-title":"Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis","volume":"7","author":"Lehrer","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2022.05.004","article-title":"Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET)\u2014extended long-term outcomes","author":"Harrow","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2022.08.016_b0115","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.euo.2019.05.007","article-title":"Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies","volume":"2","author":"Zaorsky","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0120","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/02841860600954875","article-title":"A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma","volume":"45","author":"Svedman","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0125","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.ijrobp.2011.02.040","article-title":"Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma","volume":"82","author":"Zelefsky","year":"2012","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0130","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.21037\/jtd.2017.10.108","article-title":"Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma\u2014a multicenter analysis of the German working group \u201cStereotactic Radiotherapy\u201d","volume":"9","author":"Hoerner-Rieber","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.euf.2022.08.016_b0135","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijrobp.2019.07.023","article-title":"Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer","volume":"105","author":"Zhang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2022.08.016_b0140","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13014-015-0528-z","article-title":"Local control rates of metastatic renal cell carcinoma (RCC) to thoracic, abdominal, and soft tissue lesions using stereotactic body radiotherapy (SBRT)","volume":"10","author":"Altoos","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0145","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2018.04.008","article-title":"Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the GETUG Group","volume":"98","author":"Meyer","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euf.2022.08.016_b0150","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0155","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2021.12.006","article-title":"Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma\u2014the RAPPORT trial","volume":"81","author":"Siva","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.08.016_b0160","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.20.02363","article-title":"Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0165","unstructured":"NCCN. Clinical practice guidelines in oncology: kidney cancer. V 4.2022."},{"key":"10.1016\/j.euf.2022.08.016_b0170","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2022.08.016_b0175","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.clon.2021.12.021","article-title":"Risk-group classification by recursive partitioning analysis of patients affected by oligometastatic renal cancer treated with stereotactic radiotherapy","volume":"34","author":"Franzese","year":"2022","journal-title":"Clin Oncol R Coll Radiol"},{"key":"10.1016\/j.euf.2022.08.016_b0180","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1634\/theoncologist.2016-0078","article-title":"Molecular subtypes improve prognostic value of international metastatic renal cell carcinoma database consortium prognostic model","volume":"22","author":"de Velasco","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.euf.2022.08.016_b0185","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0190","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/PPO.0000000000000434","article-title":"Definition, biology, and history of oligometastatic and oligoprogressive disease","volume":"26","author":"Foster","year":"2020","journal-title":"Cancer J Sudbury Mass"},{"key":"10.1016\/j.euf.2022.08.016_b0195","doi-asserted-by":"crossref","first-page":"e034626","DOI":"10.1136\/bmjopen-2019-034626","article-title":"What is the optimum systemic treatment for advanced\/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis","volume":"10","author":"Cao","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.euf.2022.08.016_b0200","doi-asserted-by":"crossref","first-page":"100692","DOI":"10.1016\/j.adro.2021.100692","article-title":"Stereotactic ablative radiation therapy for oligoprogressive renal cell carcinoma","volume":"6","author":"Schoenhals","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0205","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.euo.2021.12.001","article-title":"Phase II trial of stereotactic ablative radiation for oligoprogressive metastatic kidney cancer","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0210","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","article-title":"Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study","volume":"80","author":"Cheung","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.08.016_b0215","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10585-021-10131-w","article-title":"The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) Genitourinary Study Group","volume":"38","author":"Franzese","year":"2021","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.euf.2022.08.016_b0220","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2022.08.016_b0225","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13014-017-0893-x","article-title":"Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial","volume":"12","author":"De Wolf","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0230","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13014-021-01937-9","article-title":"Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma","volume":"16","author":"Liu","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0235","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1200\/JCO.2020.38.6_suppl.614","article-title":"Combination of dual immune checkpoint inhibition with stereotactic radiation in metastatic renal cell carcinoma","volume":"38","author":"Hammers","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0240","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2021.09.016","article-title":"Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES study","volume":"81","author":"Masini","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.08.016_b0245","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1200\/JCO.20.00290","article-title":"Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma","volume":"39","author":"McBride","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2022.08.016_b0250","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat Rev Clin Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545692200205X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545692200205X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:54:56Z","timestamp":1762498496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240545692200205X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S240545692200205X"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2022.08.016","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2022.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}